New Analyses Demonstrate Versatility and Continued Efficacy of TALVEY™ in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

/PRNewswire/ -- Johnson & Johnson announced today an analysis from the Phase 1/2 MonumenTAL-1 study of TALVEY™ (talquetamab-tgvs) in patients with relapsed or...

Related Keywords

United States ,California ,San Francisco ,American ,Christie Corbett ,Satu Glawe ,Christoph Heuck ,American Society Of Hematology ,None Of Janssen Research Development ,Hematology Clinical Development ,Johnson ,European Commission ,Janssen Research Development ,Eastern Cooperative Oncology Group ,Janssen Biotech Inc ,University Of California ,Myeloma Program ,International Myeloma Working Group ,Exchange Commission ,Annual Meeting ,Ajai Chari ,Multiple Myeloma Program ,Clinical Medicine ,Pivotal Phase ,Highlight Reported Continued Efficacy ,Reduced Intensity ,Vice President ,Johnson Innovative ,Independent Review Committee ,Multiple Myeloma ,Risk Evaluation ,Mitigation Strategy ,Release Syndrome ,Weight Loss ,Fetal Toxicity ,Boxed Warning ,Innovative Medicine ,Janssen Research ,Janssen Biotech ,Private Securities Litigation Reform Act ,Annual Report ,Note Regarding Forward Looking ,Quarterly Reports ,Johnson Amp ,Biotechnology ,Health Care Amp Hospitals ,Medical Pharmaceuticals ,Pharmaceuticals ,Clinical Trials Amp Medical Discoveries ,